This is a Notice of Intent to negotiate with only one source. The U.S. Government intends to acquire for the SNS 500,000 doses of a licensed anthrax vaccine with options to procure up to an additional 14,000,000 doses. Currently there is only one manufacturer who can supply FDA licensed anthrax vaccine: Emergent BioSolutions of Lansing, Michigan.



The Government intends to enter sole source negotiations with Emergent BioSolutions using the authority of 41 USC 253(c)(1). This notice of intent is not a request for proposal (RFP). The Government expects to make one award on or about 9/25/08. The determination by the Government not to compete the proposed contract under full and open competition procedures based upon responses to this notice is solely within the discretion of the Government.



Interested parties may identify their interest and capabilities in response to this notice of intent by submitting a capability statement by 9/5/08 to Michelle T. Gray, Contracting Officer, at Michelle.Gray@hhs.gov.



Any additional inquiries or comments to this announcement must reference the synopsis, RFP-DHHS-BARDA-08-26 and should be submitted to Michelle T. Gray.



This proposed acquisition is subject to the availability of funds.

Total not-to-exceed contract value for the purchase of up to 14.5 million doses of AVA for the SNS.